1. Home
  2. STVN vs BLCO Comparison

STVN vs BLCO Comparison

Compare STVN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • BLCO
  • Stock Information
  • Founded
  • STVN 1949
  • BLCO 1853
  • Country
  • STVN Italy
  • BLCO Canada
  • Employees
  • STVN N/A
  • BLCO N/A
  • Industry
  • STVN Containers/Packaging
  • BLCO Ophthalmic Goods
  • Sector
  • STVN Consumer Discretionary
  • BLCO Health Care
  • Exchange
  • STVN Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • STVN 5.7B
  • BLCO 5.6B
  • IPO Year
  • STVN 2021
  • BLCO 2022
  • Fundamental
  • Price
  • STVN $19.27
  • BLCO $12.25
  • Analyst Decision
  • STVN Buy
  • BLCO Hold
  • Analyst Count
  • STVN 7
  • BLCO 12
  • Target Price
  • STVN $26.93
  • BLCO $18.73
  • AVG Volume (30 Days)
  • STVN 365.9K
  • BLCO 700.9K
  • Earning Date
  • STVN 03-06-2025
  • BLCO 04-30-2025
  • Dividend Yield
  • STVN 0.29%
  • BLCO N/A
  • EPS Growth
  • STVN N/A
  • BLCO N/A
  • EPS
  • STVN 0.45
  • BLCO N/A
  • Revenue
  • STVN $1,143,012,735.00
  • BLCO $4,791,000,000.00
  • Revenue This Year
  • STVN $8.60
  • BLCO $6.43
  • Revenue Next Year
  • STVN $12.43
  • BLCO $5.59
  • P/E Ratio
  • STVN $45.67
  • BLCO N/A
  • Revenue Growth
  • STVN 1.72
  • BLCO 15.56
  • 52 Week Low
  • STVN $16.56
  • BLCO $12.92
  • 52 Week High
  • STVN $31.41
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • STVN 41.47
  • BLCO 25.26
  • Support Level
  • STVN $20.11
  • BLCO $13.88
  • Resistance Level
  • STVN $21.21
  • BLCO $14.70
  • Average True Range (ATR)
  • STVN 1.02
  • BLCO 0.54
  • MACD
  • STVN -0.15
  • BLCO -0.18
  • Stochastic Oscillator
  • STVN 8.51
  • BLCO 2.37

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: